VDR and osteoporosis: Kashiwagi et al. (2013) designed, synthesized, and biologically evaluated a series of nonsecosteroidal Vitamin D Receptor (VDR) agonists to assess their therapeutic potential in addressing osteoporosis and bone mineral density (BMD) loss.